Phase Ia/Ib dose-escalation study of the anti-TIGIT  tiragolumab as a single agent and in combination with atezolizumab in advanced solid tumors - Johanna C Bendell #AACR20 $RHHBY $MRK $RCUS $MREO $SGEN 3/x

PD-L1 expression (1% or higher) used as surrogate for TIGIT https://t.co/AxQ9Hub2VA